🕵️ Cogent Biosciences, Inc. ($COGT)
SEC insider & ownership activity, last 12 months · CIK 1622229 · every row links its SEC filing
Over the last 12 months insiders sold $383.9M with no open-market buying against it. Fairmount Funds Management LLC sold $370.0M in discretionary trades (Jan–Mar). Fairmount Funds Management LLC trimmed 9.9% → 8.6%; Fairmount Healthcare Fund II GP LLC trimmed 9.9% → 8.6%. No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
0 buyers, $0 (0 lots) · 6 sellers, $383.9M (8 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 0 | – | 2 | $370.0M | Mar 31, 2026 |
| John Robinson | 0 | – | 1 | $3.5M | Dec 26, 2025 |
| Jessica Sachs | 0 | – | 1 | $3.2M | Dec 26, 2025 |
| John Green | 0 | – | 1 | $3.0M | Dec 26, 2025 |
| Evan D. Kearns | 0 | – | 1 | $2.5M | Dec 26, 2025 |
| Morris Arlene | 0 | – | 2 | $1.7M | Aug 27, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| FMR LLC | 15.0% | 13G | Feb 12, 2025 | filing ↗ | |
| Abigail P. Johnson | 15.0% | 13G | Feb 12, 2025 | filing ↗ | |
| Fairmount Funds Management LLC | 8.6% | 13D | Mar 31, 2026 | filing ↗ | |
| Fairmount Healthcare Fund II GP LLC | 8.6% | 13D | Mar 31, 2026 | filing ↗ | |
| BlackRock, Inc. | 8.0% | 13G | Jul 27, 2026 | filing ↗ | |
| Bong Y. Koh | 5.8% | 13G | Apr 11, 2025 | filing ↗ | |
| Vanguard Capital Management | 5.1% | 13G | Jul 31, 2026 | filing ↗ |
Planned insider sales (Form 144)
| Seller | Planned | Approx. sale date | |
|---|---|---|---|
| Arlene Morris | $1.7M | Aug 27, 2026 | filing ↗ |
| Fairmount Healthcare Fund II L.P. | $242.6M | Mar 31, 2026 | filing ↗ |
| Fairmount Healthcare Fund II L.P. | $127.4M | Jan 22, 2026 | filing ↗ |
| Jessica Sachs | $3.2M | Dec 26, 2025 | filing ↗ |
| John Robinson | $3.5M | Dec 26, 2025 | filing ↗ |
| John Green | $3.0M | Dec 26, 2025 | filing ↗ |
| Evan D. Kearns | $2.5M | Dec 26, 2025 | filing ↗ |
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Material agreement (1.01) | Sep 1, 2026 | filing ↗ |
| Other events (8.01) | Aug 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 10, 2026 | filing ↗ |
| Earnings (2.02) | Aug 10, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 10, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 9, 2026 | filing ↗ |
| Earnings (2.02) | May 5, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 5, 2026 | filing ↗ |
| Earnings (2.02) | Feb 17, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Feb 17, 2026 | filing ↗ |
| Other events (8.01) | Dec 6, 2025 | filing ↗ |
| Material agreement (1.01) | Nov 18, 2025 | filing ↗ |
| New financial obligation (2.03) | Nov 18, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 18, 2025 | filing ↗ |
| Material agreement (1.01) | Nov 11, 2025 | filing ↗ |
| Other events (8.01) | Nov 11, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 11, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 10, 2025 | filing ↗ |
| Other events (8.01) | Nov 10, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 10, 2025 | filing ↗ |
| Earnings (2.02) | Nov 3, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 3, 2025 | filing ↗ |